Sign In
Buy BMRN
$56.47
+1.81 (+3.31%)
At Close: Jun 04, 2026
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (NASDAQ: ISRG) and Amgen (NASDAQ: AMGN) - Markets
02:46pm, Thursday, 18'th Jun 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:44pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:04pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
01:01pm, Thursday, 18'th Jun 2020
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does n
Pfizer, Sangamo flesh out hemophilia gene therapy data ahead of phase 3
01:00pm, Thursday, 18'th Jun 2020
There’s a pivotal trial in the offing for Pfizer and Sangamo’s hemophilia A gene therapy, but, in the meantime, the duo is unveiling updated phase 1/2 data. The highest dose of the treatment helpe
Car-T Cells Might Hold The Secret To The Fountain Of Youth
12:43pm, Thursday, 18'th Jun 2020
In mice, they can eliminate the cells partly responsible for many diseases of aging, researchers report. In other news: hemophilia gene therapy and concerns over AbbVie-Allergan merger.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Armata Pharmaceuticals
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:34pm, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17) * Adverum Biotechnologies Inc (NASDAQ: ADVM) * Affim
BioMarin Pharmaceutical’s (BMRN) “Buy” Rating Reaffirmed at SunTrust Banks
03:44am, Thursday, 18'th Jun 2020
BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “buy” rating restated by SunTrust Banks in a note issued to investors on Wednesday, TipRanks reports. They presently have a $109.00 price ob
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors | MarketScreener
08:06pm, Wednesday, 17'th Jun 2020uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
08:05pm, Wednesday, 17'th Jun 2020
~ Biopharma Executive Brings 35 Years of Research and Development Leadership ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2020 -- uniQure N.V. (NASDAQ: QURE), a leading gene.
BioMarin’s hemophilia gene therapy still prevents bleeding at four years
01:20pm, Wednesday, 17'th Jun 2020
BioMarin’s experimental hemophilia gene therapy, expected to be approved in the U.S. this year, still prevents bleeding in patients treated four years ago.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigati
SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 s
